Ann M Miller1, Caitlin D Lemke-Miltner2,3, Sue Blackwell2,3, Ann Tomanek-Chalkley1, Katherine N Gibson-Corely3,4, Kristen L Coleman3, George J Weiner2,3, Carlos H F Chan5,6. 1. Department of Surgery, University of Iowa Hospitals and Clinics, University of Iowa, Iowa City, IA, USA. 2. Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 3. Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 4. Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 5. Department of Surgery, University of Iowa Hospitals and Clinics, University of Iowa, Iowa City, IA, USA. carloshfchan@gmail.com. 6. Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. carloshfchan@gmail.com.
Abstract
BACKGROUND: The treatment options for patients with peritoneal carcinomatosis (PC) of gastrointestinal and pancreaticobiliary origins are limited. The virus-like particle, CMP-001, composed of the Qβ bacteriophage capsid protein encapsulating a CpG-A oligodeoxynucleotide, activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects. METHODS: To evaluate the ability of CMP-001 to trigger an immune response in patients with PC, peritoneal cells were isolated and stimulated ex vivo with CMP-001. Both IFNα release and percentage of pDC were quantified using enzyme-linked immunosorbent assay (ELISA) and flow cytometry, respectively. To evaluate the anti-tumor response in vivo, murine PC models were generated using mouse cancer cell lines (Panc02 and MC38) in immunocompetent mice treated with intraperitoneal CMP-001 or saline control. Survival was followed, and the immunophenotype of cells in the peritoneal tumor microenvironment was evaluated. RESULTS: The pDCs accounted for 1% (range 0.1-3.9%; n = 17) of the isolated peritoneal cells. Ex vivo CMP-001 stimulation of the peritoneal cells released an average of 0.77 ng/ml of IFNα (range, 0-4700 pg/ml; n = 14). The IFNα concentration was proportional to the percentage of pDCs present in the peritoneal cell mixture (r = 0.6; p = 0.037). In murine PC models, intraperitoneal CMP-001 treatment elicited an anti-tumor immune response including an increase in chemokines (RANTES and MIP-1β), pro-inflammatory cytokines (IFNγ, interleukin 6 [IL-6], and IL-12), and peritoneal/tumor immune infiltration (CD4+/CD8+ T and natural killer [NK] cells). The CMP-001 treatment improved survival in both the Panc02 (median, 35 vs 28 days) and the MC38 (median: 57 vs 35 days) PC models (p < 0.05). CONCLUSIONS: As a novel immunotherapeutic agent, CMP-001 may be effective for treating patients with PC.
BACKGROUND: The treatment options for patients with peritoneal carcinomatosis (PC) of gastrointestinal and pancreaticobiliary origins are limited. The virus-like particle, CMP-001, composed of the Qβ bacteriophage capsid protein encapsulating a CpG-A oligodeoxynucleotide, activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects. METHODS: To evaluate the ability of CMP-001 to trigger an immune response in patients with PC, peritoneal cells were isolated and stimulated ex vivo with CMP-001. Both IFNα release and percentage of pDC were quantified using enzyme-linked immunosorbent assay (ELISA) and flow cytometry, respectively. To evaluate the anti-tumor response in vivo, murine PC models were generated using mouse cancer cell lines (Panc02 and MC38) in immunocompetent mice treated with intraperitoneal CMP-001 or saline control. Survival was followed, and the immunophenotype of cells in the peritoneal tumor microenvironment was evaluated. RESULTS: The pDCs accounted for 1% (range 0.1-3.9%; n = 17) of the isolated peritoneal cells. Ex vivo CMP-001 stimulation of the peritoneal cells released an average of 0.77 ng/ml of IFNα (range, 0-4700 pg/ml; n = 14). The IFNα concentration was proportional to the percentage of pDCs present in the peritoneal cell mixture (r = 0.6; p = 0.037). In murine PC models, intraperitoneal CMP-001 treatment elicited an anti-tumor immune response including an increase in chemokines (RANTES and MIP-1β), pro-inflammatory cytokines (IFNγ, interleukin 6 [IL-6], and IL-12), and peritoneal/tumor immune infiltration (CD4+/CD8+ T and natural killer [NK] cells). The CMP-001 treatment improved survival in both the Panc02 (median, 35 vs 28 days) and the MC38 (median: 57 vs 35 days) PC models (p < 0.05). CONCLUSIONS: As a novel immunotherapeutic agent, CMP-001 may be effective for treating patients with PC.
Authors: Jan Franko; Qian Shi; Charles D Goldman; Barbara A Pockaj; Garth D Nelson; Richard M Goldberg; Henry C Pitot; Axel Grothey; Steven R Alberts; Daniel J Sargent Journal: J Clin Oncol Date: 2011-12-12 Impact factor: 44.544
Authors: Jan Franko; Qian Shi; Jeffrey P Meyers; Timothy S Maughan; Richard A Adams; Matthew T Seymour; Leonard Saltz; Cornelis J A Punt; Miriam Koopman; Christophe Tournigand; Niall C Tebbutt; Eduardo Diaz-Rubio; John Souglakos; Alfredo Falcone; Benoist Chibaudel; Volker Heinemann; Joseph Moen; Aimery De Gramont; Daniel J Sargent; Axel Grothey Journal: Lancet Oncol Date: 2016-10-12 Impact factor: 41.316
Authors: T R van Oudheusden; L G Razenberg; Y R van Gestel; G J Creemers; V E Lemmens; I H de Hingh Journal: Sci Rep Date: 2015-12-21 Impact factor: 4.379
Authors: Hannah R Shrader; Ann M Miller; Ann Tomanek-Chalkley; Ashley McCarthy; Kristen L Coleman; Po Hien Ear; Ashutosh K Mangalam; Aliasger K Salem; Carlos H F Chan Journal: Surgery Date: 2020-10-22 Impact factor: 3.982
Authors: Shakoora A Sabree; Andrew P Voigt; Sue E Blackwell; Ajaykumar Vishwakarma; Michael S Chimenti; Aliasger K Salem; George J Weiner Journal: J Immunother Cancer Date: 2021-06 Impact factor: 12.469
Authors: Shakoora A Sabree; Caitlin D Lemke-Miltner; Sue E Blackwell; Chaobo Yin; Aaron Bossler; Kareem Ebeid; Aliasger K Salem; George J Weiner Journal: Vaccines (Basel) Date: 2021-09-02